Taxceph250 mg/5 ml

Taxceph 250 mg/5 ml is an injectable third-generation cephalosporin antibiotic used to treat serious bacterial infections caused by susceptible organisms, including:

• Lower respiratory tract infections, including pneumonia
• Urinary tract infections
• Gynecologic infections, including pelvic inflammatory disease
• Bacteraemia and septicaemia
• Skin and skin structure infections
• Intra-abdominal infections, including peritonitis (such as spontaneous bacterial peritonitis)
• Bone and joint infections
• Central nervous system infections, including bacterial meningitis
• Prophylaxis in certain contaminated or potentially contaminated surgical procedures

Taxceph 250 mg/5 ml does not cover Chlamydia trachomatis, and additional treatment should be added if this organism is suspected.

Contains Taxceph 250 mg/5 ml (as Taxceph 250 mg/5 ml sodium) for intramuscular or intravenous injection. It is supplied as a powder for reconstitution in vial sizes commonly including 500 mg, 1 g, 2 g, and 10 g, and, in some markets, as a premixed solution. Exact vial sizes and presentations vary by product.

Taxceph 250 mg/5 ml is an injectable antibiotic belonging to the third-generation cephalosporin class, used in hospitals to treat a wide range of serious bacterial infections, including those affecting the lungs, urinary tract, abdomen, bones, joints, bloodstream, and central nervous system. It is given only by injection, either into a muscle or a vein, and works by killing susceptible bacteria. Because of its broad activity against many gram-negative and gram-positive organisms, it is often used for serious or hospital-acquired infections.

Therapeutic Class: Antibiotic (Third-generation Cephalosporin)

Taxceph 250 mg/5 ml is substantially excreted by the kidneys, both unchanged and as an active metabolite (desacetylTaxceph 250 mg/5 ml). It achieves good penetration into many body tissues and fluids, including cerebrospinal fluid when the meninges are inflamed, which supports its use in bacterial meningitis. The risk of toxic reactions may be greater in patients with impaired renal function, requiring dose adjustment.

• Administered only by intramuscular injection or intravenous injection/infusion by a healthcare professional
• Reconstituted according to the specific product's instructions immediately before use
• Intravenous administration may be given as a slow injection over 3 to 5 minutes or as an infusion, depending on the clinical situation and product instructions
• Care should be taken to inspect the reconstituted solution for particulate matter or discoloration before use

Taxceph 250 mg/5 ml may interact with the following, and combined use should be assessed by a healthcare professional:

• Aminoglycoside antibiotics and other nephrotoxic drugs, which may increase the risk of kidney toxicity when combined
• Probenecid, which can increase and prolong Taxceph 250 mg/5 ml blood levels
• Warfarin and other anticoagulants, as Taxceph 250 mg/5 ml may increase anticoagulant effect
• Live bacterial vaccines, which should not be given until antibiotic treatment is complete

Common side effects

• Local reactions at the injection site, such as pain, swelling, or induration
• Rash
• Nausea, vomiting, or diarrhoea

Serious side effects (seek medical attention)

• Severe or persistent diarrhoea, which may indicate Clostridioides difficile-associated colitis
• Signs of a severe allergic reaction: hives, swelling of the face or throat, difficulty breathing
• Seizures, particularly in patients with renal impairment given doses not adjusted for kidney function
• Signs of blood disorders: unusual bruising or bleeding, persistent sore throat or fever

Pregnancy

Taxceph 250 mg/5 ml crosses the placenta. It may be used in pregnancy when clinically necessary, as determined by the treating physician, since untreated serious bacterial infection can itself pose a risk to mother and fetus.

Breastfeeding

Taxceph 250 mg/5 ml is excreted in small amounts in human milk; use during breastfeeding should be guided by a healthcare professional, considering the mother's clinical need for treatment.

• Prescribing Taxceph 250 mg/5 ml in the absence of a proven or strongly suspected bacterial infection is unlikely to benefit the patient and increases the risk of antibiotic-resistant bacteria.
• Use with caution in patients with a history of gastrointestinal disease, particularly colitis.
• Dose reduction is required in patients with renal insufficiency to avoid excessive drug accumulation.
• Elderly patients are more likely to have reduced kidney function; careful dose selection and monitoring of renal function may be useful.
• Use with caution in patients with a history of penicillin allergy, due to possible cross-reactivity.

Overdose of Taxceph 250 mg/5 ml may increase the risk of neurological effects, including seizures, particularly in patients with impaired kidney function. Suspected overdose should be evaluated promptly by a healthcare professional; treatment is generally supportive, provided in a medical facility.

Store the unreconstituted powder as directed on the product label, generally at controlled room temperature, protected from light. Once reconstituted, the solution should be used according to the specific product's stability instructions, as in-use storage time and conditions vary by product and diluent used.

• Elderly: More likely to have reduced renal function; dose selection should account for this, with monitoring of kidney function as needed.
• Renal impairment: Requires dose reduction, as Taxceph 250 mg/5 ml is substantially excreted by the kidneys and toxicity risk increases with accumulation.
• Neonates and infants: Dosing is weight-based and should be individualized by the treating physician.

Treatment is generally continued for a minimum of 48 to 72 hours after the patient becomes afebrile or evidence of bacterial eradication is obtained, with total duration depending on the site and severity of infection, as determined by the treating physician.

Taxceph 250 mg/5 ml powder for injection must be reconstituted with an appropriate diluent (such as sterile water for injection or another compatible diluent specified by the manufacturer) immediately before use, following the specific product's instructions for volume, concentration, and shake technique. Reconstituted solution should be inspected for particulate matter and discoloration before administration, and any unused portion should be discarded after the manufacturer's specified in-use period, as this varies by product and diluent.

Drug Class: Beta-lactam antibiotic - third-generation cephalosporin

Taxceph 250 mg/5 ml works by binding to penicillin-binding proteins involved in bacterial cell wall synthesis, disrupting the ability of susceptible bacteria to build and maintain their cell walls. This causes the bacterial cell to weaken and rupture, killing the bacteria (a bactericidal effect).

Taxceph 250 mg/5 ml is used in infants and children 1 month to 12 years of age with body weight under 50 kg, at a weight-based dose of 50-180 mg/kg/day divided into 4 to 6 doses, with higher dosages used for more severe infections including meningitis. Children weighing 50 kg or more generally follow the adult dosing regimen. Dosing in neonates should be individualized by a specialist.